Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound of formula (I):



(I)

or a pharmaceutically acceptable salt~~, prodrug,~~ or hydrate ~~or solvate~~ thereof where:

R^1 is H;

R^2 is a substituted or unsubstituted ~~(C_1-C_8)~~ (C_6-C_8)alkyl, ~~(C_3-C_7)~~ (C_3-C_9)cycloalkyl, (C_3-C_9)aryl, (C_3-C_9)heteroaryl, ~~amide, amine,~~ ~~(C_1-C_8)~~ (C_6-C_8) alcohol, (C_3-C_9)heterocyclyl, ~~heterocycloalkyl,~~ (C_1-C_8)alkyl(C_3-C_9)aryl, (C_1-C_8)alkylamine, (C_1-C_8)alkylamide; or R^1 and R^2 taken together with the nitrogen to which they are attached form a substituted or unsubstituted (C_3-C_9)heterocyclyl ~~heterocycloalkyl~~ or heteroaryl;

R^3 is independently selected from the group consisting of H, (C_1-C_8)alkyl, halo, (C_1-C_8)alkoxy, (C_1-C_8)alkyl-SO_2-, ~~sulfonyl,~~ cyano, and ~~keto~~ (C_1-C_8)alkylC(=O)-;

n is an integer from 0-5;

with the proviso that the compound is not 3-amino-6-phenyl-pyrazine-2-carboxylic acid butylamide or 3-amino-6-phenyl-pyrazine-2-carboxylic acid (2-hydroxy-ethyl)-amide.

Claim 2 (original): A compound of claim 1, wherein R^3 is H, bromo, chloro, cyano, methoxy, (C_1-C_8)alkyl-SO_2-, or (C_1-C_8)alkylC(=O)-.

Claim 3 (original): A compound of claim 1, wherein n is 0-4.

Claim 4 (original): A compound of claim 3, wherein n is 0-1.

Claim 5 (withdrawn): A compound of formula (II):



(II)

or a pharmaceutically acceptable salt~~, prodrug,~~ or hydrate ~~or solvate~~ thereof where:
R^1 is H;
R^2 is a substituted or unsubstituted (C_1-C_8)alcohol, (C_3-C_9)cycloalkyl, ~~(C_3-C_9)heterocycloalkyl~~, (C_3-C_9)heterocyclyl, (C_3-C_9)heteroaryl, (C_1-C_8)alkylamine, (C_1-C_8)alkyl(C_3-C_9)aryl, or (C_1-C_8)alkylamide; or R^1 and R^2 taken together with the nitrogen to which they are attached form a substituted or unsubstituted (C_3-C_9) heterocyclyl ~~heterocycloalkyl~~, or heteroaryl group;
Het is a substituted or unsubstituted heterocyclyl or heteroaryl group containing at least one heteroatom selected from N, O and S.

Claim 6 (withdrawn): A compound of claim 5, wherein Het is a substituted or unsubstituted (C_5-C_{10})heterocyclyl or heteroaryl group containing at least one heteroatom selected from N, O and S.

Claim 7 (withdrawn): A compound of claim 6, wherein Het is a substituted or unsubstituted furanyl, thienyl, pyridyl, or benzofuranyl group.

Claim 8 (withdrawn): A compound of formula (III):



(III)

or a pharmaceutically acceptable salt~~, prodrug,~~ or hydrate ~~or solvate~~ thereof where:

R^1 is H;

R^2 is a substituted or unsubstituted (C_1-C_8)alcohol;

Ar is a substituted or unsubstituted (C_3-C_9)aryl group;

with the proviso that the compound is not 3-amino-6-phenyl-pyrazine-2-carboxylic acid butylamide or 3-amino-6-phenyl-pyrazine-2-carboxylic acid (2-hydroxy-ethyl)-amide.

Claim 9 (withdrawn): A compound of claim 8, wherein R^2 is a substituted or unsubstituted (C_1-C_5)alcohol.

Claim 10 (withdrawn): A compound of claim 9, wherein R^2 is a substituted or unsubstituted (C_3-C_5)alcohol.

Claim 11 (withdrawn): A compound of claim 8, wherein Ar is a substituted or unsubstituted naphthyl group.

Claim 12 (withdrawn): A pharmaceutical composition comprising a compound of any one of claims 1-11 and a pharmaceutically acceptable carrier.

Claim 13 (withdrawn): A method of preventing or treating a TGF-related disease state in a mammal (animal or human) comprising the step of administering a therapeutically effective amount of a compound of any one of claims 1-11 to the animal or human suffering from the TGF-related disease state.

Claim 14 (withdrawn): A method of claim 13, wherein said TGF-related disease state is selected from the group consisting of cancer, glomerulonephritis, diabetic nephropathy, hepatic fibrosis, pulmonary fibrosis, intimal hyperplasia and restenosis, scleroderma, and dermal scarring.

Claim 15 (currently amended): A compound of claim 1 wherein

R^2 is a substituted or unsubstituted $(C_1\text{-}C_8)$alkyl$(C_3\text{-}C_9)$aryl;

R^3 is independently selected from the group consisting of H, $(C_1\text{-}C_8)$alkyl, halo, $(C_1\text{-}C_8)$alkoxy, $(C_1\text{-}C_8)$alkyl-SO_2-, ~~sulfonyl,~~ cyano, and ~~keto~~ $(C_1\text{-}C_8)$alkylC(=O)-; and

n is 0-4.

Claim 16 (previously submitted): A compound of claim 15, where R^3 is independently selected from the group consisting of H, or bromo, chloro, and methoxy.

Claim 17 (previously submitted): A compound of claim 16 wherein n=0 and R^2 is an unsubstituted $(C_1\text{-}C_8)$alkyl$(C_3\text{-}C_9)$aryl.

Claim 18 (previously submitted): A compound of claim 17 wherein said $(C_1\text{-}C_8)$alkyl$(C_3\text{-}C_9)$aryl is CH_2 phenyl.

Claim 19 (previously submitted): The compound 3-amino-6-phenyl-pyrazine-2-carboxylic acid benzylamide.

Claim 20 (new) A compound of formula (I):



(I)

or a pharmaceutically acceptable salt or hydrate thereof where:

R^1 is H;

R^2 is a substituted or unsubstituted $(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_9)$cycloalkyl, $(C_3\text{-}C_9)$aryl, $(C_3\text{-}C_9)$heteroaryl, $(C_1\text{-}C_8)$alcohol, $(C_3\text{-}C_9)$heterocyclyl, $(C_1\text{-}C_8)$alkyl$(C_3\text{-}C_9)$aryl, $(C_1\text{-}C_8)$alkylamine, $(C_1\text{-}C_8)$alkylamide; or R^1 and R^2 taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclyl or heteroaryl;

R^3 is independently selected from the group consisting of $(C_1\text{-}C_8)$alkyl, halo, $(C_1\text{-}C_8)$alkoxy, $(C_1\text{-}C_8)$alkyl-SO_2-, cyano, and $(C_1\text{-}C_8)$alkylC(=O)-;

n is an integer from 1-5;

with the proviso that the compound is not 3-amino-6-phenyl-pyrazine-2-carboxylic acid butylamide or 3-amino-6-phenyl-pyrazine-2-carboxylic acid (2-hydroxy-ethyl)-amide.